Company / R&D Expense
Royalty Pharma plc R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$452.0M
FY2025
5-year range
$2.0M / $452.0M
FY2021-FY2025
Trend
+22500.0%
vs FY2024
Sector context
#38 of 210
Health Care
What the data says
R&D Expense changed +22500% YoY in FY2025, a notable deviation from the 7-year average annual change of +3235%.
Based on SEC 10-K filings.
$452M in FY2025 with a 5-year CAGR of +2.9%. Top quartile in the Health Care sector.
Improved from $52M to $452M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +158.1%
- 5-Year CAGR
- +2.9%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 210This company $452.0M Sector average $644.0M
▼
-29.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.9%, indicating consistent growth.
- In FY2025, r&d expense increased 22500.0% year-over-year.
- Ranks #38 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- Strong profit margin: 38.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $452.0M | +22500.0% |
| FY2024 | $2.0M | -96.2% |
| FY2023 | $52.0M | +97.8% |
| FY2022 | $26.3M | -68.3% |
| FY2021 | $83.0M | -78.9% |
| FY2020 | $392.6M | +372.8% |
| FY2019 | $83.0M | -78.9% |
| FY2018 | $392.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026